Happy Hippo’s Ethical Failures in Kratom Marketing and Addiction Disclosure

Happy Hippo Sold an Opioid Without Saying So. Millions of Americans Paid the Price.
EvilCorporations.com — Corporate Misconduct Accountability Project
Critical Severity

Happy Hippo Sold an Opioid Without Saying So. Millions of Americans Paid the Price.

A kratom company hid its products’ opioid-level addiction risks behind a smiling cartoon mascot, candy-flavored packaging, and free samples at gas stations.

TL;DR

Happy Hippo LLC sold kratom products at gas stations and smoke shops using colorful, cartoon-heavy packaging that made them look like candy or energy drinks. What the company never told consumers: kratom acts on the same opioid receptors in the brain as heroin and morphine, carries the same addiction and dependency risks, and produces brutal withdrawal symptoms when stopped. The company knew. It sold free samples anyway. It buried the only warning it had in a dropdown menu buried on a product page. Millions of consumers, many of whom had never heard of kratom, were left to discover they were addicted the hard way. This is not an accident. This is a business model.

Share this page. Demand warning labels on all kratom products. Support the class action plaintiffs fighting for accountability.

$1.3B
U.S. kratom industry annual revenue (2021)
15M
Estimated annual kratom users in the U.S.
1M
Americans using kratom monthly
45K+
Reddit “Quitting Kratom” forum members as of Oct. 2024
$80–90
Plaintiff’s monthly kratom spend at addiction’s peak
$50/day
One user’s habit cost, with a newborn and a mortgage

The Allegations: A Breakdown

⚠️
Core Allegations
What they did
01 Happy Hippo sold kratom products that interact with the same opioid receptors (mu-opioid receptors) as heroin, morphine, and fentanyl, yet placed zero disclosure of this fact on product labels, packaging, or primary marketing materials. high
02 The company deliberately framed its kratom energy shots as sugar-free, caffeine-free fitness supplements suitable for “fast-paced, active lifestyles,” using language designed to mislead consumers into equating kratom with a standard energy drink. high
03 Happy Hippo used a brightly colored smiling hippopotamus mascot named “Puddles,” candy-inspired product names (Taffy, Huckleberry, Fruit Punch, Blood Orange), and a “Live Happy” slogan that plaintiffs allege was designed to appeal to younger consumers and suppress perception of risk. high
04 The only addiction-related disclaimer on the website was hidden inside a dropdown menu on individual product pages, reading only that kratom “may have addictive properties.” No warning appeared on physical product packaging. high
05 Happy Hippo offered free kratom samples through its website and authorized retail stores with no addiction warning of any kind, a tactic the complaint compares directly to street-level drug distribution. high
06 The class action alleges violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, breach of implied warranty, unjust enrichment, and fraud by omission on behalf of a nationwide class of purchasers. med
☣️
Public Health and Safety
What kratom actually does to the body
01 Kratom’s active alkaloids (mitragynine and 7-hydroxymitragynine) bind to the mu-opioid receptor, the same receptor activated by morphine and heroin, producing euphoria, sedation, and analgesia at higher doses. high
02 Kratom withdrawal symptoms mirror traditional opioid withdrawal: irritability, anxiety, depression, restless leg syndrome, muscle and bone pain, diarrhea, chills, and extreme dysphoria. high
03 Long-term users report depression, anhedonia, anxiety, and reduced sex drive as documented consequences of sustained kratom use. high
04 Kratom’s addiction is described as uniquely “sneaky”: because users are unaware of its opioid nature, they mistake early withdrawal symptoms for something else, then take more kratom believing company marketing claims that it will “help them feel better.” high
05 Two-thirds of the estimated 1 million Americans who use kratom monthly do so daily, a usage pattern consistent with dependency rather than voluntary supplementation. med
06 Because kratom remains largely unknown to mainstream consumers and lacks established recovery resources in the U.S., addicted users face a particularly isolated and under-supported path to sobriety. high
🏛️
Corporate Accountability Failures
What Happy Hippo knew and chose not to disclose
01 Kratom’s addictive properties have been documented in scientific literature since at least 1988, and its pharmacological similarities to opioids were well-established by the time Happy Hippo was selling its products. high
02 Happy Hippo imports some of its kratom from Thailand, a country that has studied kratom addiction for over a century and banned the substance in 1943. The company’s supply chain relationships provided direct access to this documented knowledge. high
03 The company employs specialized labs to isolate and extract kratom alkaloids for a subset of its products, demonstrating technical knowledge of kratom’s pharmacological mechanisms while simultaneously refusing to warn consumers about them. high
04 Happy Hippo received user reports about kratom’s addictive potential and had direct interactions with Southeast Asian growers and distributors who disclosed kratom’s addictive nature. The company chose profit over disclosure. high
05 The complaint alleges that Happy Hippo knowingly omitted addiction warnings because it understood they were “material facts” that would harm sales, constituting fraud by omission under California and federal consumer protection law. high
💰
Profit Over People
Revenue built on concealed addiction
01 The kratom industry generates $1.3 billion annually in the United States. Happy Hippo participates in this revenue stream by engineering consumer ignorance rather than correcting it. high
02 Happy Hippo’s business model depends structurally on repeat purchases driven by addiction: once users are dependent, they continue purchasing not because they want to but because stopping causes severe withdrawal symptoms. high
03 The company’s free sample program directly expanded its customer base by introducing consumers to an addictive substance without disclosing its addictive nature, converting unsuspecting first-time users into paying customers. high
04 Plaintiff L.S. spent $80 to $90 per month at the height of his addiction. One forum user described a $50-per-day habit maintained alongside a newborn child and a mortgage. The financial burden of kratom dependency falls entirely on the people least informed about what they were buying. high
📣
The PR Machine
Branding designed to suppress risk perception
01 Happy Hippo marketed kratom energy shots as suitable alternatives to traditional caffeinated pre-workouts and positioned the products as tools for “acute focus, concentration, and appetite suppression,” framing an opioid-acting substance as a performance supplement. high
02 The company promoted kratom as an herbal treatment for pain, opioid withdrawal symptoms, depression, and anxiety, making therapeutic claims for a product with no FDA approval and severe undisclosed addiction risks. high
03 A website banner advertised “Magic Hippo” kratom under the heading “Magical Mind and Comfortable Reality” alongside benefits labeled “Discomfort Relief,” “Joyful Spirit,” and “Restful Sleep,” none of which disclosed opioid-receptor activity or addiction risk. med
04 Happy Hippo’s “Happiness Guarantee,” bright-pink packaging, cartoon hippo mascot, and candy-inspired product names function as a coordinated branding strategy that obscures the product’s narcotic pharmacology behind a veneer of wholesome fun. high
05 The complaint explicitly compares Happy Hippo’s youth-targeting marketing tactics to those of tobacco and vape companies whose deceptive advertising practices resulted in mass addiction among younger Americans. high

Timeline of Events

1836
Kratom’s first documented scientific use recorded; Malay workers used it as a substitute for opium.
1943
Thailand bans kratom after extensive study of its addictive properties, recognizing it as a public health risk.
1952
Malaysia bans kratom under the Poisons Act following documentation of addiction and dependency.
1988
Kratom addiction in Southeast Asia begins being formally studied and documented by U.S. scientists and researchers.
2007
A study finds 2.3% of Thailand’s population uses kratom, with many developing dependency to avoid withdrawal.
~2021
Plaintiff L.S. first purchases Happy Hippo kratom on the recommendation of a smoke shop employee. No addiction warning is provided or visible on packaging.
2021
The American Kratom Association estimates the U.S. kratom industry has grown to $1.3 billion in annual revenue with up to 15 million users.
2022
Plaintiff’s addiction peaks. He spends $80 to $90 per month on Happy Hippo kratom powder. Attempts to stop trigger severe opioid-like withdrawal symptoms.
Oct 4, 2024
Class action complaint filed in the U.S. District Court, Central District of California (Case No. 2:24-cv-8566). CLRA notice letters sent to Happy Hippo LLC. Jury trial demanded.

Direct Quotes from the Legal Record

QUOTE 1 What reasonable consumers don’t know Core Allegations
“What reasonable consumers do not know, and what Defendant fails to disclose, is that the ‘active ingredients’ in its kratom Products are equivalent to opioids.”

💡 This establishes the core legal claim: Happy Hippo concealed the pharmacological identity of its product from the people buying it.

QUOTE 2 Addiction is the business model Profit Over People
“Defendant relies on its Products’ vague packaging and consumers’ limited knowledge of kratom pharmacology to get unsuspecting users addicted to its Products and reaps profits from these addictions.”

💡 The complaint alleges the concealment is not negligence but strategy. The ignorance of consumers is the product.

QUOTE 3 Candy packaging for an opioid The PR Machine
“The Products look like a watermelon candy more than they do a hard opioid.”

💡 This is the central visual deception: packaging designed to look harmless functions as a tool of consumer fraud.

QUOTE 4 The “free sample” trap Core Allegations
“Just like a street-level drug dealer might do, Defendant has authorized stores, and on information and belief, in some cases, instructed them, to give the Products out as free samples.”

💡 Offering free samples of a product that causes physical dependency, without disclosing that dependency risk, is alleged to be deliberate predatory conduct.

QUOTE 5 The opioid crisis gets a new supplier Corporate Accountability Failures
“The United States is going through an opiate crisis that is shaking the foundations of our society. Amid this crisis, Defendant is creating more addicts for no reason other than to line its pockets.”

💡 The complaint situates Happy Hippo’s conduct squarely inside the broader opioid epidemic, not as an isolated consumer protection violation but as active participation in a public health catastrophe.

QUOTE 6 A user describes losing everything Public Health and Safety
“I had lost my JOB, my boyfriend, and my personality. It landed me in the hospital many times actually. I was losing hair, my eyes looked horrible, my skin was horribly dry, and I was miserable. I decided to go to REHAB. Effing rehab for this sh!t.”

💡 This is a real person describing the real cost of being deceived by a company that knew exactly what it was selling. This is not a side effect. This is the predictable outcome of selling an opioid-acting substance without warning.

QUOTE 7 The withdrawal described Public Health and Safety
“Last night may have been one of the roughest nights of my life. It felt like a bad acid trip. I got zero sleep. The RLS was so bad I kept getting out of bed… It felt like I was being electrocuted!!!”

💡 The suffering described in this user account is medically consistent with documented opioid withdrawal. Happy Hippo’s packaging said nothing about the possibility of this outcome.

QUOTE 8 The $50-a-day hole Profit Over People
“My habit was $50 a day, and with a newborn and mortgage etc I’m still trying to climb out of that hole.”

💡 Kratom addiction is not abstract. It is rent money, baby formula, and grocery budgets redirected to a company that never warned its customers this was the risk.

QUOTE 9 Addiction sneaks up Public Health and Safety
“What is particularly insidious about kratom, they describe, is that because they are unaware of kratom’s negative side effects and its addictive potential, when they begin to experience the negative symptoms attributable to addiction in the early stages of taking kratom products, they do not attribute it to the kratom.”

💡 This is not a warning Happy Hippo placed anywhere. Consumers had to learn it from their own bodies, after the addiction had already taken hold.

QUOTE 10 The hidden disclaimer Corporate Accountability Failures
“There is a dropdown menu at the bottom of the Product page entitled ‘Kratom Use Disclaimer’ that when clicked on, reveals text stating ‘[k]ratom may have addictive properties that can cause dependency issues.'”

💡 “May have addictive properties” buried in a dropdown is not a warning. It is legal cover. A consumer at a gas station register, seeing a pink cartoon bottle, never sees this text.

Commentary

Is kratom actually as dangerous as an opioid?
Yes, according to documented science. Kratom’s active compounds bind to the mu-opioid receptor, the same receptor targeted by morphine and heroin. Health professionals classify it as a “quasi-opiate.” The withdrawal symptoms are clinically consistent with opioid withdrawal. The addictive potential is not disputed in the medical literature. What is disputed is whether kratom sellers have a legal obligation to say so plainly on their packaging. This lawsuit argues they do, and that Happy Hippo’s failure to do so was intentional and predatory.
Why is kratom even legal in the United States?
Kratom occupies a legal gray zone. The FDA has not approved it as a dietary supplement and has issued warnings about its risks. The DEA has considered scheduling it as a controlled substance. But as of this filing, kratom remains legal and largely unregulated federally, which is precisely why companies like Happy Hippo have been able to sell it at gas stations without the warning labels required for regulated substances. This lawsuit’s demand for mandatory warning labels represents one of the most direct legal challenges to that regulatory vacuum.
Is this lawsuit legitimate?
The complaint was filed in federal court in October 2024 by two established consumer litigation firms: Lynch Carpenter, LLP and Bursor and Fisher, P.A. The claims are grounded in California consumer protection statutes (UCL, FAL, CLRA), breach of implied warranty, unjust enrichment, and fraud by omission. The pharmacological science cited in the complaint is consistent with published medical literature. Whether the court ultimately certifies the class and finds liability will depend on proceedings, but the legal theory is serious and the evidentiary basis described in the filing is substantial.
Why didn’t consumers just research kratom before buying it?
This framing places responsibility on victims rather than the seller, and it reflects exactly the logic the complaint challenges. Most consumers have never heard of kratom. Happy Hippo’s packaging actively discouraged suspicion: it looked like a candy or energy drink, used cheerful branding, and made no mention of opioids. Consumers at a gas station counter have no particular reason to suspect that an unregulated “herbal supplement” sold alongside vitamins and sports drinks could trigger the same withdrawal crisis as prescription opioids. Companies with superior pharmacological knowledge have a legal duty to disclose material risks. That duty does not transfer to consumers simply because they failed to conduct toxicological research before buying a $10 energy shot.
Who is most harmed by this?
The people most harmed are working-class consumers who purchased kratom at gas stations and smoke shops, often seeking relief from pain, low energy, or opioid withdrawal, and who developed severe addictions with no understanding of what was happening to them. The accounts in the complaint describe job loss, hospitalizations, rehab stays, destroyed relationships, and financial devastation. These are not wealthy consumers with easy access to detox facilities and addiction specialists. They are people for whom a $50-per-day kratom habit, taken on while caring for a newborn or paying rent, represents a genuine financial and personal catastrophe.
How does this connect to the broader opioid crisis?
The complaint says it directly: Happy Hippo is “creating more addicts” while the United States is in the grip of an opioid epidemic. Kratom is marketed heavily as a tool to manage opioid withdrawal, which means it is targeting people who are already vulnerable to addiction. Introducing them to an opioid-acting substance without disclosure is not a solution to the opioid crisis. It is an extension of it, conducted under cover of “natural supplement” branding. The same regulatory failures and corporate indifference that fueled the prescription opioid crisis created the conditions for kratom companies to operate with similar consequences and far less scrutiny.
What can I do to prevent this from happening again?
Several concrete actions are available. First, if you or someone you know purchased Happy Hippo kratom products, contact the attorneys of record at Lynch Carpenter, LLP or Bursor and Fisher, P.A. to inquire about class membership. Second, contact your federal representatives and demand that the FDA and DEA address the kratom regulatory gap and require mandatory addiction warning labels on all kratom products sold in the United States. Third, share this case widely. Consumer awareness is the primary tool available while regulation lags. Fourth, support organizations working on addiction recovery and drug policy reform, particularly those focused on unregulated substance risks. The kratom industry’s rapid growth has outpaced both regulatory attention and public awareness. That gap is exactly where companies like Happy Hippo profit.
Will Happy Hippo actually face consequences?
That depends on the court. The complaint seeks actual damages, punitive damages, restitution, disgorgement of profits, and a court order requiring corrective advertising. It also seeks injunctive relief: a legal requirement that Happy Hippo add adequate addiction warnings to its packaging. Even a settlement without full liability findings could produce meaningful outcomes for class members and force labeling changes. The history of tobacco, vaping, and pharmaceutical litigation shows that consumer class actions, even when settled rather than litigated to verdict, can produce structural changes in how industries disclose product risks. The plaintiffs and their counsel are asking for accountability. Whether the legal system delivers it is a separate question, and one that demands sustained public attention.

💡 Explore Corporate Misconduct by Category

Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.

Aleeia
Aleeia

I'm Aleeia, the creator of this website.

I have 6+ years of experience as an independent researcher covering corporate misconduct, sourced from legal documents, regulatory filings, and professional legal databases.

My background includes a Supply Chain Management degree from Michigan State University's Eli Broad College of Business, and years working inside the industries I now cover.

Every post on this site was either written or personally reviewed and edited by me before publication.

Learn more about my research standards and editorial process by visiting my About page

Articles: 1737
🏳️‍⚧️ trans rights are human rights 🏳️‍⚧️
Theme